youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
RHO:ETR
Roche Holding AG
€416.20
arrow_upward
+0.24%(+1.00) 1D
Oct 19, 5:35:57 PM GMT+2 · EUR
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RHO...
Open
€416.00
High
€417.20
Low
€415.20
Mkt. cap
371.89B
Avg. vol.
478.00
Volume
91.00
52-wk high
€420.80
52-wk low
€292.20
No. of employees
113K
Open
€416.00
High
€417.20
Low
€415.20
Mkt. cap
371.89B
Avg. vol.
478.00
Volume
91.00
52-wk high
€420.80
52-wk low
€292.20
No. of employees
113K
News stories
From web sources and news partners
Euronext Markets: Real-time Stock Market Data | live
·
4 hours ago
Roche puts future German investments 'on hold'
Euronext Markets: Real-time Stock Market Data | live
·
9 hours ago
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion
Yahoo Finance
·
10 hours ago
Roche to review investment in Germany over health insurance reform
Investing.com
·
10 hours ago
RBC Capital reiterates Roche stock rating on strong momentum
Profile
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in the Forbes Global 2000 was 76.
The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights, with Swiss pharma firm Novartis owning a further third of its shares until 2021.
F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations. Wikipedia
About Roche Holding AG
CEOThomas Schinecker
Employees113K
FoundedOct 1, 1896
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websiteroche.com
Next call in 2 days
Thu, Oct 22, 2:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (CHF)
- GAAP EPS / Est. (CHF)
- / -
Revenue / Est. (CHF)
- / 15.71B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in CHF | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 15.75B | 15.75B | 15.73B | 15.73B |
Cost of goods sold | 4.21B | 4.21B | 3.93B | 3.93B |
Cost of revenue | 4.21B | 4.21B | 3.93B | 3.93B |
Research and development expenses | 3.15B | 3.15B | 2.99B | 2.99B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 3.59B | 3.59B | 3.22B | 3.22B |
Operating expense | 6.82B | 6.82B | 6.11B | 6.11B |
Total operating expenses | 11.03B | 11.03B | 10.03B | 10.03B |
Operating income | 4.72B | 4.72B | 5.69B | 5.69B |
Other non operating income | -10.00M | -10.00M | -15.00M | -15.00M |
EBT including unusual items | 3.69B | 3.69B | 4.49B | 4.49B |
EBT excluding unusual items | 4.37B | 4.37B | 5.38B | 5.38B |
Income tax expense | 709.00M | 709.00M | 824.00M | 824.00M |
Effective tax rate | 19.20% | 19.20% | 18.37% | 18.37% |
Other operating expenses | 77.50M | 77.50M | -99.00M | -99.00M |
Net income | 2.74B | 2.74B | 3.44B | 3.44B |
Net profit margin | 17.36% | 17.36% | 21.85% | 21.85% |
Earnings per share | - | - | - | - |
Interest and investment income | 45.00M | 45.00M | 43.50M | 43.50M |
Interest expense | -289.50M | -289.50M | -282.00M | -282.00M |
Net interest expenses | -244.50M | -244.50M | -238.50M | -238.50M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 5.50B | 5.50B | 6.48B | 6.48B |
Gain or loss from assets sale | -21.50M | -21.50M | -2.50M | -2.50M |